Citigroup Inc Adma Biologics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 387,226 shares of ADMA stock, worth $7.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

387,226

Previous 110,088 251.74%

Holding current value

$7.14 Million

Previous $1.23 Million 529.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$11.21 - $20.03 $3.11 Million - $5.55 Million	277,138 Added 251.74%	387,226 $7.74 Million
Q2 2024 Aug 12, 2024	SELL	$5.98 - $11.18 $3.13 Million - $5.84 Million	-522,671 Reduced 82.6%	110,088 $1.23 Million
Q1 2024 May 10, 2024	BUY	$4.4 - $6.74 $1.62 Million - $2.49 Million	368,769 Added 139.69%	632,759 $4.18 Million
Q4 2023 Feb 09, 2024	SELL	$3.08 - $4.52 $39,146 - $57,449	-12,710 Reduced 4.59%	263,990 $1.19 Million
Q3 2023 Nov 09, 2023	SELL	$3.47 - $4.61 $37,680 - $50,059	-10,859 Reduced 3.78%	276,700 $990,000
Q2 2023 Aug 10, 2023	SELL	$3.12 - $4.22 $1.6 Million - $2.16 Million	-512,042 Reduced 64.04%	287,559 $1.06 Million
Q1 2023 May 11, 2023	BUY	$3.01 - $3.87 $1.35 Million - $1.74 Million	449,032 Added 128.09%	799,601 $2.65 Million
Q4 2022 Feb 09, 2023	SELL	$2.47 - $3.88 $438,669 - $689,084	-177,599 Reduced 33.63%	350,569 $1.36 Million
Q3 2022 Nov 10, 2022	BUY	$2.03 - $2.86 $1.04 Million - $1.47 Million	514,041 Added 3638.71%	528,168 $1.28 Million
Q2 2022 Aug 10, 2022	BUY	$1.43 - $2.2 $14,091 - $21,678	9,854 Added 230.61%	14,127 $28,000
Q1 2022 May 12, 2022	SELL	$1.28 - $1.83 $2,218 - $3,171	-1,733 Reduced 28.85%	4,273 $8,000
Q4 2021 Feb 10, 2022	BUY	$1.09 - $1.66 $6,546 - $9,969	6,006 New	6,006 $8,000

Others Institutions Holding ADMA

# of Institutions

318

Shares Held

184M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.62B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account